Lemzoparlimab, a Novel Anti-CD47 Monoclonal Antibody, in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS): Initial Clinical Results

  • Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients.
  • For patients received initial dose over 3 months, the ORR is 80.6% and for patients received initial dose over 6 months the ORR is 86.7%, CR rate 40%.
  • Lemzoparlimab does not require priming dosing with no unexpected safety signals in combination therapy with AZA.
  • For subjects achieving CR, remaining gene mutation frequency such as TP53, TET2 and RUNX1 were significantly decreased.
  • A randomized Phase 3 trial in higher-risk MDS is planned.